Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Identification of novel therapeutic targets in acute leukemias with NRAS mutations using a pharmacologic approach.

Blood - 14 May 2015

Nonami Atsushi, Sattler Martin, Weisberg Ellen, Liu Qingsong, Zhang Jianming, Patricelli Matthew P, Christie Amanda L, Saur Amy M, Kohl Nancy E, Kung Andrew L, Yoon Hojong, Sim Taebo, Gray Nathanael S, Griffin James D

Abstract excerpt

Oncogenic forms of NRAS are frequently associated with hematologic malignancies and other cancers, making them important therapeutic targets. Inhibition of individual downstream effector molecules (eg, RAF kinase) have been complicated by the rapid development of resistance or activation of bypas...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bridged Bicyclo Compounds, Heterocyclic
Share to Cell Cycle Checkpoints

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Screening Assays, Antitumor

Share to Germinal Center Kinases

Share to GTP Phosphohydrolases

Share to Leukemia

Share to Pyrimidinones

Share to Small Molecule Libraries

Source

Open in PubMed Open full text

Identifiers

PMID: 25833960
DOI: 10.1182/blood-2014-12-615906
PMCID: PMC4432008

Genes

NRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-25833960-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Identification of novel therapeutic targets in acute leukemias with NRAS mutations using a pharmacologic approach.PMID 25833960Read ↗

First SAR Study for Overriding NRAS Mutant Driven Acute Myeloid Leukemia.Semantic proximity Read ↗

Preclinical efficacy of MEK inhibition in Nras-mutant AML.Semantic proximity Read ↗

Mutant NRASQ61 shares signaling similarities across various cancer types--potential implications for future therapies.Semantic proximity Read ↗

Oncogenic NRAS rapidly and efficiently induces CMML- and AML-like diseases in mice.Semantic proximity Read ↗

MicroRNA-708 emerges as a potential candidate to target undruggable NRAS.Semantic proximity Read ↗

Nras(G12D/+) promotes leukemogenesis by aberrantly regulating hematopoietic stem cell functions.Semantic proximity Read ↗

Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial.Semantic proximity Read ↗

Endogenous oncogenic Nras mutation initiates hematopoietic malignancies in a dose- and cell type-dependent manner.Semantic proximity Read ↗

Development of small-molecule probes that selectively kill cells induced to express mutant RAS.Semantic proximity Read ↗

Hematopoiesis and leukemogenesis in mice expressing oncogenic NrasG12D from the endogenous locus.Semantic proximity Read ↗

Role of farnesyltransferase inhibitors in hematologic malignancies.Semantic proximity Read ↗

Endogenous oncogenic Nras mutation promotes aberrant GM-CSF signaling in granulocytic/monocytic precursors in a murine model of chronic myelomonocytic leukemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.